Evaluation of a Carbapenem-Saving Strategy Using Empirical Combination Regimen of Piperacillin-Tazobactam and Amikacin in Hemato-Oncology Patients
Journal of Korean Medical Science
; : e17-2019.
Article
in En
| WPRIM
| ID: wpr-719585
Responsible library:
WPRO
ABSTRACT
We implemented a carbapenem-saving strategy in hemato-oncology patients from 2013, using an empirical combination of piperacillin-tazobactam and amikacin for high-risk hemato-oncology patients with febrile neutropenia, who remain hemodynamically unstable > 72 hours despite initial cefepime treatment. All-cause mortality was not different between the two periods (6.54 and 6.57 deaths per 1,000 person-day, P = 0.926). Group 2 carbapenem use significantly decreased after strategy implementation (78.43 vs. 67.43 monthly days of therapy, P = 0.018), while carbapenem-resistant gram-negative bacilli did not show meaningful changes during the study period. Our carbapenem-saving strategy could effectively suppress carbapenem use without an increase of overall mortality.
Key words
Full text:
1
Index:
WPRIM
Main subject:
Amikacin
/
Mortality
/
Febrile Neutropenia
Type of study:
Prognostic_studies
Limits:
Humans
Language:
En
Journal:
Journal of Korean Medical Science
Year:
2019
Type:
Article